Charter Trust Co. acquired a new stake in shares of Novo Nordisk A/S (NYSE:NVO) in the first quarter, HoldingsChannel.com reports. The firm acquired 4,790 shares of the company’s stock, valued at approximately $288,000.
Other hedge funds and other institutional investors also recently modified their holdings of the company. WASHINGTON TRUST Co bought a new position in shares of Novo Nordisk A/S during the first quarter valued at $27,000. Patriot Financial Group Insurance Agency LLC bought a new position in shares of Novo Nordisk A/S in the first quarter valued at about $30,000. TD Capital Management LLC bought a new position in shares of Novo Nordisk A/S in the first quarter valued at about $30,000. Westside Investment Management Inc. bought a new position in shares of Novo Nordisk A/S in the first quarter valued at about $36,000. Finally, Americana Partners LLC bought a new position in shares of Novo Nordisk A/S in the fourth quarter valued at about $42,000. 6.69% of the stock is owned by institutional investors.
A number of research analysts recently issued reports on NVO shares. Morgan Stanley reaffirmed an “equal weight” rating on shares of Novo Nordisk A/S in a report on Monday, May 18th. Bank of America raised Novo Nordisk A/S from a “neutral” rating to a “buy” rating in a report on Monday, March 16th. Societe Generale reaffirmed a “sell” rating on shares of Novo Nordisk A/S in a report on Thursday, May 7th. UBS Group cut Novo Nordisk A/S from a “buy” rating to a “neutral” rating in a report on Monday, May 11th. Finally, JPMorgan Chase & Co. reaffirmed an “overweight” rating on shares of Novo Nordisk A/S in a report on Wednesday, May 13th. Two research analysts have rated the stock with a sell rating, eight have assigned a hold rating and four have issued a buy rating to the stock. The company has an average rating of “Hold” and an average target price of $163.55.
NYSE:NVO traded down $1.46 on Thursday, hitting $65.10. 66,706 shares of the stock were exchanged, compared to its average volume of 1,899,517. The stock has a market capitalization of $153.63 billion, a price-to-earnings ratio of 25.58, a P/E/G ratio of 2.32 and a beta of 0.46. Novo Nordisk A/S has a 52 week low of $47.24 and a 52 week high of $66.74. The company has a debt-to-equity ratio of 0.05, a quick ratio of 0.73 and a current ratio of 1.00. The company’s 50-day moving average price is $64.20 and its 200 day moving average price is $60.27.
Novo Nordisk A/S (NYSE:NVO) last announced its quarterly earnings data on Wednesday, May 6th. The company reported $0.75 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.68 by $0.07. The firm had revenue of $5 billion during the quarter, compared to analysts’ expectations of $4.70 billion. Novo Nordisk A/S had a return on equity of 73.87% and a net margin of 31.91%. As a group, equities research analysts predict that Novo Nordisk A/S will post 2.69 earnings per share for the current year.
About Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes Care and Obesity, and Biopharmaceuticals. The Diabetes Care and Obesity segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral anti-diabetic products, obesity, and other chronic diseases.
Further Reading: Insider Trading
Want to see what other hedge funds are holding NVO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novo Nordisk A/S (NYSE:NVO).
Receive News & Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related companies with MarketBeat.com's FREE daily email newsletter.